recurrent osteosarcoma
Showing 1 - 25 of 8,005
Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)
Recruiting
- Recurrent Osteosarcoma
- humanized anti-GD2 antibody
- GM-CSF
-
Los Angeles, California
- +2 more
Dec 22, 2022
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent Trial in United States (Regorafenib 40 MG, Regorafenib 20MG,
Recruiting
- Osteosarcoma
- +3 more
- Regorafenib 40 MG
- +2 more
-
Los Angeles, California
- +7 more
Jan 19, 2023
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic Trial in Miami (Chemotherapy (gemcitabine & docetaxel) plus BIO-11006)
Active, not recruiting
- Osteosarcoma Metastatic
- Ewing's Sarcoma Metastatic
- Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
-
Miami, FloridaNicklaus Children's Hospital
Nov 8, 2022
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma Trial in France (Cabozantinib S-malate, Laboratory
Active, not recruiting
- Metastatic Ewing Sarcoma
- +9 more
- Cabozantinib S-malate
- Laboratory Biomarker Analysis
-
Bordeaux, France
- +10 more
Nov 26, 2022
Osteosarcoma, Bone Tumor, Bone Sarcoma Trial
Not yet recruiting
- Osteosarcoma
- +25 more
- (no location specified)
Aug 24, 2022
DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
Completed
- Localized Osteosarcoma
- +2 more
- Laboratory Biomarker Analysis
-
Philadelphia, PennsylvaniaChildrens Oncology Group
Mar 11, 2022
Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in
Not yet recruiting
- Liver Transplant; Complications
- +3 more
- multi-kinase inhibitors in combination with bevacizumab
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023
Pulmonary Osteosarcoma Trial (RNA-LP vaccine)
Not yet recruiting
- Pulmonary Osteosarcoma
- RNA-LP vaccine
- (no location specified)
Jan 25, 2023
Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,
Recruiting
- Recurrent Neuroblastoma
- +3 more
- Cyclophosphamide
- +2 more
-
Palo Alto, California
- +3 more
Jan 25, 2023
Osteosarcoma, Recurrent Osteosarcoma Trial in United States (Trastuzumab Deruxtecan)
Suspended
- Osteosarcoma
- Recurrent Osteosarcoma
- Trastuzumab Deruxtecan
-
Birmingham, Alabama
- +27 more
Oct 21, 2022
Osteogenic Sarcoma Recurrent Trial in Hackensack, Houston (Iscador*P)
Not yet recruiting
- Osteogenic Sarcoma Recurrent
-
Hackensack, New Jersey
- +1 more
Feb 3, 2023
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,
Recruiting
- High Risk Neuroblastoma
- +4 more
- Biospecimen Collection
- +6 more
-
Los Angeles, California
- +10 more
Jan 19, 2023
Osteosarcoma Trial in United States (Avelumab, Questionnaires)
Active, not recruiting
- Osteosarcoma
- Avelumab
- Questionnaires
-
Los Angeles, California
- +3 more
Aug 22, 2022
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma Trial in Houston (Durvalumab,
Recruiting
- Metastatic Angiosarcoma
- +7 more
- Durvalumab
- Oleclumab
-
Houston, TexasM D Anderson Cancer Center
Sep 21, 2021
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
High Dose Isofosfamide Through Elastomer
Active, not recruiting
- Osteosarcoma Recurrent
- Observational study
-
Bologna, Italy
- +4 more
Aug 11, 2022
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)
Recruiting
- Bone Sarcoma
- +15 more
- Aldesleukin
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 3, 2022
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Tumor in the CNS, Recurrent Diffuse Intrinsic Pontine Glioma Trial
Active, not recruiting
- Diffuse Midline Glioma, H3 K27M-Mutant
- +10 more
- FACT Complex-targeting Curaxin CBL0137
-
Birmingham, Alabama
- +19 more
Jun 29, 2022
Solid Tumor, Lymphoma, Osteosarcoma Trial in Orange (Surufatinib in combination with Gemcitabine)
Recruiting
- Solid Tumor
- +5 more
- Surufatinib in combination with Gemcitabine
-
Orange, CaliforniaChildrens Hospital Orange County
Feb 8, 2022
Recurrent Malignant Solid Tumor, Recurrent Osteosarcoma, Refractory Malignant Solid Tumor Trial in United States (Laboratory
Active, not recruiting
- Recurrent Malignant Solid Neoplasm
- +3 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +23 more
Apr 22, 2022
Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
Completed
- Osteosarcoma Recurrent
- Osteosarcoma Metastatic
- observation
-
Milan, Milano, Italy
- +7 more
Nov 24, 2021
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma Trial in United States (MM-398 (Irinotecan Sucrosofate
Recruiting
- Recurrent or Refractory Solid Tumors
- +4 more
- MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
-
Cincinnati, Ohio
- +5 more
Mar 17, 2022